<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784444</url>
  </required_header>
  <id_info>
    <org_study_id>MSDC-0602K-C009NASH</org_study_id>
    <nct_id>NCT02784444</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability &amp; Efficacy of MSDC-0602K in Patients With NASH</brief_title>
  <acronym>EMMINENCE</acronym>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cirius Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiltern International Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cirius Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blinded study of three doses of MSDC-0602K or placebo given&#xD;
      orally once daily to subjects with biopsy proven NASH with fibrosis and no cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blinded study of three doses of MSDC-0602K or placebo given&#xD;
      orally once daily to subjects with biopsy proven NASH with fibrosis and no cirrhosis. Visits&#xD;
      to the clinic will be at baseline, 1, 2, 3, 6, 9, and 12 months, with one 2- week follow-up&#xD;
      visit.&#xD;
&#xD;
      Safety will be assessed by monitoring of vital signs, 12 lead electrocardiogram (ECG),&#xD;
      physical examinations, safety labs, and adverse events (AEs).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2016</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Hepatic Histological Improvement in NAS</measure>
    <time_frame>12 months (360 days)</time_frame>
    <description>A decrease of at least 2 points in NAS at 12 months.&#xD;
At least a 1 point reduction in either ballooning or inflammation from baseline to 12 months.&#xD;
no increase in CRN fibrosis score (i.e., an increase of 1 stage or more) from baseline to 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Resolution of NASH With no Worsening of Fibrosis at 12 Months.</measure>
    <time_frame>12 months (360 days)</time_frame>
    <description>CRN ballooning score of 0 at 12-months&#xD;
CRN inflammation score of 0 or 1 at 12-months&#xD;
No increase in CRN fibrosis score from baseline to 12-months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Improvement of Fibrosis (CRN Staging Score) by at Least 1 Stage With no Worsening of NASH at 12 Months.</measure>
    <time_frame>12 months (360 days)</time_frame>
    <description>Decrease in fibrosis CRN staging score of &gt;= 1 full stage from baseline to 12 months&#xD;
No increase in ballooning CRN score from baseline to 12 months&#xD;
No increase in inflammation CRN score from baseline to 12-months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in NAFLD Activity Score (NAS)</measure>
    <time_frame>12 months (360 days)</time_frame>
    <description>NAS is the sum of the scores of steatosis, inflammation, and ballooning. It has a range of 0 to 8 with higher scores indicating worse disease severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRN Steatosis Score</measure>
    <time_frame>12 months (360 days)</time_frame>
    <description>Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRN Inflammation Score</measure>
    <time_frame>12 months (360 days)</time_frame>
    <description>Inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRN Ballooning Score</measure>
    <time_frame>12 months (360 days)</time_frame>
    <description>Hepatocellular ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe hepatocellular ballooning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CRN Fibrosis Staging Score</measure>
    <time_frame>12 months (360 days)</time_frame>
    <description>Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>MSDC-0602K Dose 1 capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MSDC-0602K Dose 1 capsule taken once daily for 360 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSDC-0602K Dose 2 capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MSDC-0602K Dose 2 capsules taken once daily for 360 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSDC-0602K Dose 3 capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MSDC-0602K Dose 3 capsules taken once daily for 360 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo capsule taken once daily for 360 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSDC-0602K</intervention_name>
    <description>MSDC-0602K capsules</description>
    <arm_group_label>MSDC-0602K Dose 1 capsules</arm_group_label>
    <arm_group_label>MSDC-0602K Dose 2 capsules</arm_group_label>
    <arm_group_label>MSDC-0602K Dose 3 capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Selected Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects 18 years of age or greater&#xD;
&#xD;
          -  Histological evidence of NASH, based on biopsy, with a NAS (NASH CRN scoring) ≥ 4 with&#xD;
             a score of at least 1 in each component of NAS.&#xD;
&#xD;
          -  Histological evidence of liver fibrosis defined as NASH CRN System fibrosis score F1&#xD;
             to F3.&#xD;
&#xD;
          -  Subjects with type 2 diabetes mellitus (DM) must be under stable and reasonable&#xD;
             control.&#xD;
&#xD;
          -  Male and female subjects who are taking Vitamin E should be on a stable dose of&#xD;
             Vitamin E (if ≥ 400 IU) for a period of at least 3 months prior to randomization.&#xD;
&#xD;
          -  Females should be either postmenopausal (at least 12 months since last menses) or&#xD;
             surgically sterilized (bilateral tubal ligation or hysterectomy). Males with female&#xD;
             partners of child-bearing potential must agree to use adequate contraceptive methods&#xD;
             (including a condom, plus one other form of contraception) if engaging in sexual&#xD;
             intercourse.&#xD;
&#xD;
          -  Willing and able to sign an informed consent document indicating understanding the&#xD;
             purpose of and procedures required for the study and willingness to participate in the&#xD;
             study.&#xD;
&#xD;
        Selected Exclusion Criteria:&#xD;
&#xD;
          -  Known history of HIV.&#xD;
&#xD;
          -  Prior liver transplantation.&#xD;
&#xD;
          -  Other well-documented causes of active chronic liver disease.&#xD;
&#xD;
          -  History of cirrhosis and/or hepatic decompensation including ascites, hepatic&#xD;
             encephalopathy or variceal bleeding.&#xD;
&#xD;
          -  History of alcohol abuse or drug abuse within 6 months of Screening.&#xD;
&#xD;
          -  Type 1 diabetes mellitus.&#xD;
&#xD;
          -  Current or history of recent (≤ 6 months) use of ursodeoxycholic acid.&#xD;
&#xD;
          -  Use of concomitant medications with a known significant metabolism by CYP2C8 or&#xD;
             CPY2C9.&#xD;
&#xD;
          -  History of diabetic ketoacidosis or hyperosmolar non-ketotic coma within 6 months&#xD;
             prior to randomization.&#xD;
&#xD;
          -  History of heart failure (including CHF) or previous cardiovascular event (myocardial&#xD;
             infarct, by-pass surgery, or PTCA) within the past 6 months prior to randomization.&#xD;
&#xD;
          -  Blood pressure greater than 160/100 mmHg.&#xD;
&#xD;
          -  Participation in an investigational study or received an investigational drug within&#xD;
             30 days or 5 half-lives (whichever is longer) prior to study drug administration.&#xD;
&#xD;
          -  Malignancy, including leukemia and lymphoma (excluding basal cell and squamous skin&#xD;
             cell cancers and localized prostrate cancer) treated within the last 2 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Dittrich, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cirius Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bastrop</city>
        <state>Louisiana</state>
        <zip>71220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Monroe</city>
        <state>Louisiana</state>
        <zip>71291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>112301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hermitage</city>
        <state>Tennessee</state>
        <zip>37076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rollingwood</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <results_first_submitted>August 10, 2020</results_first_submitted>
  <results_first_submitted_qc>August 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2020</results_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02784444/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02784444/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching Placebo capsule taken once daily for 360 days&#xD;
Placebo: Placebo capsules</description>
        </group>
        <group group_id="P2">
          <title>MSDC-0602K 62.5 mg</title>
          <description>MSDC-0602K 62.5 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
        </group>
        <group group_id="P3">
          <title>MSDC-0602K 125 mg</title>
          <description>MSDC-0602K 125 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
        </group>
        <group group_id="P4">
          <title>MSDC-0602K 250 mg</title>
          <description>MSDC-0602K 250 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="98"/>
                <participants group_id="P4" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="86"/>
                <participants group_id="P4" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching Placebo capsule taken once daily for 360 days&#xD;
Placebo: Placebo capsules</description>
        </group>
        <group group_id="B2">
          <title>MSDC-0602K 62.5 mg</title>
          <description>MSDC-0602K 62.5 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
        </group>
        <group group_id="B3">
          <title>MSDC-0602K 125 mg</title>
          <description>MSDC-0602K 125 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
        </group>
        <group group_id="B4">
          <title>MSDC-0602K 250 mg</title>
          <description>MSDC-0602K 250 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="98"/>
            <count group_id="B4" value="101"/>
            <count group_id="B5" value="392"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="11.2"/>
                    <measurement group_id="B2" value="56.9" spread="10.3"/>
                    <measurement group_id="B3" value="56.0" spread="10.9"/>
                    <measurement group_id="B4" value="56.8" spread="10.4"/>
                    <measurement group_id="B5" value="56.1" spread="10.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age at Enrollment</title>
              <category_list>
                <category>
                  <title>&lt; 55 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 55 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="273"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>American Indian Or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black Or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian Or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="91"/>
                    <measurement group_id="B5" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hepatic Histological Improvement in NAS</title>
        <description>A decrease of at least 2 points in NAS at 12 months.&#xD;
At least a 1 point reduction in either ballooning or inflammation from baseline to 12 months.&#xD;
no increase in CRN fibrosis score (i.e., an increase of 1 stage or more) from baseline to 12 months.</description>
        <time_frame>12 months (360 days)</time_frame>
        <population>Subjects in the Modified Intent-to-Treat Set with available baseline biopsy and 12-month biopsy taken within 14 days of study drug discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo capsule taken once daily for 360 days&#xD;
Placebo: Placebo capsules</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0602K 62.5 mg</title>
            <description>MSDC-0602K 62.5 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
          <group group_id="O3">
            <title>MSDC-0602K 125 mg</title>
            <description>MSDC-0602K 125 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
          <group group_id="O4">
            <title>MSDC-0602K 250 mg</title>
            <description>MSDC-0602K 250 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hepatic Histological Improvement in NAS</title>
          <description>A decrease of at least 2 points in NAS at 12 months.&#xD;
At least a 1 point reduction in either ballooning or inflammation from baseline to 12 months.&#xD;
no increase in CRN fibrosis score (i.e., an increase of 1 stage or more) from baseline to 12 months.</description>
          <population>Subjects in the Modified Intent-to-Treat Set with available baseline biopsy and 12-month biopsy taken within 14 days of study drug discontinuation.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in response rates between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.747</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Models are adjusted for presence of diabetes mellitus, baseline fibrosis F1 versus F2/F3, and baseline NAS (0-8).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in response rates between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.575</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Models are adjusted for presence of diabetes mellitus, baseline fibrosis F1 versus F2/F3, and baseline NAS (0-8).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>2.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in response rates between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.158</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Models are adjusted for presence of diabetes mellitus, baseline fibrosis F1 versus F2/F3, and baseline NAS (0-8).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>3.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Resolution of NASH With no Worsening of Fibrosis at 12 Months.</title>
        <description>CRN ballooning score of 0 at 12-months&#xD;
CRN inflammation score of 0 or 1 at 12-months&#xD;
No increase in CRN fibrosis score from baseline to 12-months</description>
        <time_frame>12 months (360 days)</time_frame>
        <population>Analysis Population Description: Subjects in the Modified Intent-to-Treat Set with available baseline biopsy and 12-month biopsy taken within 14 days of study drug discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo capsule taken once daily for 360 days&#xD;
Placebo: Placebo capsules</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0602K 62.5 mg</title>
            <description>MSDC-0602K 62.5 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
          <group group_id="O3">
            <title>MSDC-0602K 125 mg</title>
            <description>MSDC-0602K 125 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
          <group group_id="O4">
            <title>MSDC-0602K 250 mg</title>
            <description>MSDC-0602K 250 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Resolution of NASH With no Worsening of Fibrosis at 12 Months.</title>
          <description>CRN ballooning score of 0 at 12-months&#xD;
CRN inflammation score of 0 or 1 at 12-months&#xD;
No increase in CRN fibrosis score from baseline to 12-months</description>
          <population>Analysis Population Description: Subjects in the Modified Intent-to-Treat Set with available baseline biopsy and 12-month biopsy taken within 14 days of study drug discontinuation.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in response rates between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.828</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Models are adjusted for presence of diabetes mellitus, baseline fibrosis F1 versus F2/F3, and baseline NAS (0-8).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>2.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in response rates between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.299</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Models are adjusted for presence of diabetes mellitus, baseline fibrosis F1 versus F2/F3, and baseline NAS (0-8).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>3.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in response rates between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.116</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Models are adjusted for presence of diabetes mellitus, baseline fibrosis F1 versus F2/F3, and baseline NAS (0-8).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>3.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Improvement of Fibrosis (CRN Staging Score) by at Least 1 Stage With no Worsening of NASH at 12 Months.</title>
        <description>Decrease in fibrosis CRN staging score of &gt;= 1 full stage from baseline to 12 months&#xD;
No increase in ballooning CRN score from baseline to 12 months&#xD;
No increase in inflammation CRN score from baseline to 12-months</description>
        <time_frame>12 months (360 days)</time_frame>
        <population>Analysis Population Description: Subjects in the Modified Intent-to-Treat Set with available baseline biopsy and 12-month biopsy taken within 14 days of study drug discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo capsule taken once daily for 360 days&#xD;
Placebo: Placebo capsules</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0602K 62.5 mg</title>
            <description>MSDC-0602K 62.5 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
          <group group_id="O3">
            <title>MSDC-0602K 125 mg</title>
            <description>MSDC-0602K 125 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
          <group group_id="O4">
            <title>MSDC-0602K 250 mg</title>
            <description>MSDC-0602K 250 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Improvement of Fibrosis (CRN Staging Score) by at Least 1 Stage With no Worsening of NASH at 12 Months.</title>
          <description>Decrease in fibrosis CRN staging score of &gt;= 1 full stage from baseline to 12 months&#xD;
No increase in ballooning CRN score from baseline to 12 months&#xD;
No increase in inflammation CRN score from baseline to 12-months</description>
          <population>Analysis Population Description: Subjects in the Modified Intent-to-Treat Set with available baseline biopsy and 12-month biopsy taken within 14 days of study drug discontinuation.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in response rates between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.657</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Models are adjusted for presence of diabetes mellitus, baseline fibrosis F1 versus F2/F3, and baseline NAS (0-8).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>2.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in response rates between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.332</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Models are adjusted for presence of diabetes mellitus, baseline fibrosis F1 versus F2/F3, and baseline NAS (0-8).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>3.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in response rates between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.270</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Models are adjusted for presence of diabetes mellitus, baseline fibrosis F1 versus F2/F3, and baseline NAS (0-8).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>3.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in NAFLD Activity Score (NAS)</title>
        <description>NAS is the sum of the scores of steatosis, inflammation, and ballooning. It has a range of 0 to 8 with higher scores indicating worse disease severity.</description>
        <time_frame>12 months (360 days)</time_frame>
        <population>Subjects in the Modified Intent-to-Treat Set with available baseline biopsy and 12-month biopsy taken within 14 days of study drug discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo capsule taken once daily for 360 days&#xD;
Placebo: Placebo capsules</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0602K 62.5 mg</title>
            <description>MSDC-0602K 62.5 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
          <group group_id="O3">
            <title>MSDC-0602K 125 mg</title>
            <description>MSDC-0602K 125 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
          <group group_id="O4">
            <title>MSDC-0602K 250 mg</title>
            <description>MSDC-0602K 250 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in NAFLD Activity Score (NAS)</title>
          <description>NAS is the sum of the scores of steatosis, inflammation, and ballooning. It has a range of 0 to 8 with higher scores indicating worse disease severity.</description>
          <population>Subjects in the Modified Intent-to-Treat Set with available baseline biopsy and 12-month biopsy taken within 14 days of study drug discontinuation.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.80"/>
                    <measurement group_id="O2" value="-1.0" spread="1.66"/>
                    <measurement group_id="O3" value="-1.1" spread="1.74"/>
                    <measurement group_id="O4" value="-1.2" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in changes between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.392</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model adjusted by age, sex, presence of diabetes mellitus, Vitamin E ≥ 400 IU, baseline fibrosis F1 versus F2/F3, and baseline NAS (0-8).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in changes between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.023</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model adjusted by age, sex, presence of diabetes mellitus, Vitamin E ≥ 400 IU, baseline fibrosis F1 versus F2/F3, and baseline NAS (0-8).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in changes between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.028</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model adjusted by age, sex, presence of diabetes mellitus, Vitamin E ≥ 400 IU, baseline fibrosis F1 versus F2/F3, and baseline NAS (0-8).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRN Steatosis Score</title>
        <description>Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis.</description>
        <time_frame>12 months (360 days)</time_frame>
        <population>Analysis Population Description: Subjects in the Modified Intent-to-Treat Set with available baseline biopsy and 12-month biopsy taken within 14 days of study drug discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo capsule taken once daily for 360 days&#xD;
Placebo: Placebo capsules</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0602K 62.5 mg</title>
            <description>MSDC-0602K 62.5 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
          <group group_id="O3">
            <title>MSDC-0602K 125 mg</title>
            <description>MSDC-0602K 125 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
          <group group_id="O4">
            <title>MSDC-0602K 250 mg</title>
            <description>MSDC-0602K 250 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRN Steatosis Score</title>
          <description>Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis.</description>
          <population>Analysis Population Description: Subjects in the Modified Intent-to-Treat Set with available baseline biopsy and 12-month biopsy taken within 14 days of study drug discontinuation.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.80"/>
                    <measurement group_id="O2" value="-0.6" spread="0.88"/>
                    <measurement group_id="O3" value="-0.5" spread="0.93"/>
                    <measurement group_id="O4" value="-0.7" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in changes between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.224</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model adjusted by age, sex, presence of diabetes mellitus, Vitamin E ≥ 400 IU, baseline fibrosis F1 versus F2/F3, and baseline steatosis.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in changes between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.096</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model adjusted by age, sex, presence of diabetes mellitus, Vitamin E ≥ 400 IU, baseline fibrosis F1 versus F2/F3, and baseline steatosis.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in changes between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model adjusted by age, sex, presence of diabetes mellitus, Vitamin E ≥ 400 IU, baseline fibrosis F1 versus F2/F3, and baseline steatosis.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRN Inflammation Score</title>
        <description>Inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe inflammation.</description>
        <time_frame>12 months (360 days)</time_frame>
        <population>Subjects in the Modified Intent-to-Treat Set with available baseline biopsy and 12-month biopsy taken within 14 days of study drug discontinuation</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo capsule taken once daily for 360 days&#xD;
Placebo: Placebo capsules</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0602K 62.5 mg</title>
            <description>MSDC-0602K 62.5 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
          <group group_id="O3">
            <title>MSDC-0602K 125 mg</title>
            <description>MSDC-0602K 125 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
          <group group_id="O4">
            <title>MSDC-0602K 250 mg</title>
            <description>MSDC-0602K 250 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRN Inflammation Score</title>
          <description>Inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe inflammation.</description>
          <population>Subjects in the Modified Intent-to-Treat Set with available baseline biopsy and 12-month biopsy taken within 14 days of study drug discontinuation</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.70"/>
                    <measurement group_id="O2" value="-0.1" spread="0.71"/>
                    <measurement group_id="O3" value="-0.2" spread="0.56"/>
                    <measurement group_id="O4" value="-0.1" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in changes between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.488</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model adjusted by age, sex, presence of diabetes mellitus, Vitamin E ≥ 400 IU, baseline fibrosis F1 versus F2/F3, and baseline inflammation.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in changes between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.291</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model adjusted by age, sex, presence of diabetes mellitus, Vitamin E ≥ 400 IU, baseline fibrosis F1 versus F2/F3, and baseline inflammation.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in changes between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.595</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model adjusted by age, sex, presence of diabetes mellitus, Vitamin E ≥ 400 IU, baseline fibrosis F1 versus F2/F3, and baseline inflammation.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRN Ballooning Score</title>
        <description>Hepatocellular ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe hepatocellular ballooning.</description>
        <time_frame>12 months (360 days)</time_frame>
        <population>Analysis Population Description: Subjects in the Modified Intent-to-Treat Set with available baseline biopsy and 12-month biopsy taken within 14 days of study drug discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo capsule taken once daily for 360 days&#xD;
Placebo: Placebo capsules</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0602K 62.5 mg</title>
            <description>MSDC-0602K 62.5 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
          <group group_id="O3">
            <title>MSDC-0602K 125 mg</title>
            <description>MSDC-0602K 125 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
          <group group_id="O4">
            <title>MSDC-0602K 250 mg</title>
            <description>MSDC-0602K 250 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRN Ballooning Score</title>
          <description>Hepatocellular ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe hepatocellular ballooning.</description>
          <population>Analysis Population Description: Subjects in the Modified Intent-to-Treat Set with available baseline biopsy and 12-month biopsy taken within 14 days of study drug discontinuation.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.98"/>
                    <measurement group_id="O2" value="-0.4" spread="0.94"/>
                    <measurement group_id="O3" value="-0.4" spread="0.94"/>
                    <measurement group_id="O4" value="-0.4" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in changes between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.416</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model adjusted by age, sex, presence of diabetes mellitus, Vitamin E ≥ 400 IU, baseline fibrosis F1 versus F2/F3, and baseline ballooning.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in changes between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model adjusted by age, sex, presence of diabetes mellitus, Vitamin E ≥ 400 IU, baseline fibrosis F1 versus F2/F3, and baseline ballooning.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in changes between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.220</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model adjusted by age, sex, presence of diabetes mellitus, Vitamin E ≥ 400 IU, baseline fibrosis F1 versus F2/F3, and baseline ballooning.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CRN Fibrosis Staging Score</title>
        <description>Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis.</description>
        <time_frame>12 months (360 days)</time_frame>
        <population>Analysis Population Description: Subjects in the Modified Intent-to-Treat Set with available baseline biopsy and 12-month biopsy taken within 14 days of study drug discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo capsule taken once daily for 360 days&#xD;
Placebo: Placebo capsules</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0602K 62.5 mg</title>
            <description>MSDC-0602K 62.5 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
          <group group_id="O3">
            <title>MSDC-0602K 125 mg</title>
            <description>MSDC-0602K 125 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
          <group group_id="O4">
            <title>MSDC-0602K 250 mg</title>
            <description>MSDC-0602K 250 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CRN Fibrosis Staging Score</title>
          <description>Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis.</description>
          <population>Analysis Population Description: Subjects in the Modified Intent-to-Treat Set with available baseline biopsy and 12-month biopsy taken within 14 days of study drug discontinuation.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.10"/>
                    <measurement group_id="O2" value="0.1" spread="1.07"/>
                    <measurement group_id="O3" value="-0.1" spread="1.16"/>
                    <measurement group_id="O4" value="-0.1" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in changes between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.928</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model adjusted by age, sex, diabetes mellitus, Vitamin E ≥ 400 IU, baseline fibrosis F1 vs. F2/F3, and baseline CRN fibrosis staging score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in changes between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.244</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model adjusted by age, sex, diabetes mellitus, Vitamin E ≥ 400 IU, baseline fibrosis F1 vs. F2/F3, and baseline CRN fibrosis staging score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in changes between the MSDC-0602K dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.228</p_value>
            <p_value_desc>Statistical testing was two-sided using a significance (alpha) level of 0.05. No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model adjusted by age, sex, diabetes mellitus, Vitamin E ≥ 400 IU, baseline fibrosis F1 vs. F2/F3, and baseline CRN fibrosis staging score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study treatment up to the final study visit, at an average of 1 year and 2 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching Placebo capsule taken once daily for 360 days&#xD;
Placebo: Placebo capsules</description>
        </group>
        <group group_id="E2">
          <title>MSDC-0602K 62.5 mg</title>
          <description>MSDC-0602K 62.5 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
        </group>
        <group group_id="E3">
          <title>MSDC-0602K 125 mg</title>
          <description>MSDC-0602K 125 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
        </group>
        <group group_id="E4">
          <title>MSDC-0602K 250 mg</title>
          <description>MSDC-0602K 250 mg taken once daily for 360 days&#xD;
MSDC-0602K: MSDC-0602K capsules</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Splenic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticultis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Urinary tract infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Small intestine adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Transurethral prostatetectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Dirrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jules Lee</name_or_title>
      <organization>Cirius Therapeutics Inc.</organization>
      <phone>8583336274 ext 514</phone>
      <email>jlee@ciriustx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

